

# Stephen Brand

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5750837/publications.pdf>

Version: 2024-02-01

19  
papers

960  
citations

516215

16  
h-index

794141

19  
g-index

20  
all docs

20  
docs citations

20  
times ranked

1184  
citing authors

#	ARTICLE	IF	CITATIONS
1	Reaction hijacking of tyrosine tRNA synthetase as a new whole-of-life-cycle antimalarial strategy. <i>Science</i> , 2022, 376, 1074-1079.	6.0	25
2	Discovery of Potent and Fast-Acting Antimalarial Bis-1,2,4-triazines. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 4150-4162.	2.9	14
3	Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral Leishmaniasis. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 5905-5930.	2.9	25
4	Design of proteasome inhibitors with oral efficacy in vivo against <i>Plasmodium falciparum</i> and selectivity over the human proteasome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	19
5	Optimisation of 2-(N-phenyl carboxamide) triazolopyrimidine antimalarials with moderate to slow acting erythrocytic stage activity. <i>Bioorganic Chemistry</i> , 2021, 115, 105244.	2.0	11
6	The proteasome as a target for protozoan parasites. <i>Expert Opinion on Therapeutic Targets</i> , 2019, 23, 903-914.	1.5	32
7	Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 9318-9323.	3.3	119
8	Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 1180-1202.	2.9	33
9	Pharmacological Validation of N-Myristoyltransferase as a Drug Target in <i>Leishmania donovani</i> . <i>ACS Infectious Diseases</i> , 2019, 5, 111-122.	1.8	55
10	A Molecular Hybridization Approach for the Design of Potent, Highly Selective, and Brain-Penetrant N-Myristoyltransferase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 8374-8389.	2.9	41
11	Chemical Validation of Methionyl-tRNA Synthetase as a Druggable Target in <i>Leishmania donovani</i> . <i>ACS Infectious Diseases</i> , 2017, 3, 718-727.	1.8	22
12	Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against <i>Trypanosoma cruzi</i> . <i>Journal of Medicinal Chemistry</i> , 2017, 60, 7284-7299.	2.9	31
13	Design and Synthesis of Brain Penetrant Trypanocidal N-Myristoyltransferase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 9790-9806.	2.9	14
14	Validation of N-myristoyltransferase as Potential Chemotherapeutic Target in Mammal-Dwelling Stages of <i>Trypanosoma cruzi</i> . <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004540.	1.3	25
15	Development of Small Molecule <i>Trypanosoma brucei</i> N-Myristoyltransferase Inhibitors: Discovery and Optimisation of a Novel Binding Mode. <i>ChemMedChem</i> , 2015, 10, 1821-1836.	1.6	20
16	Development of a Fluorescence-based <i>Trypanosoma cruzi</i> CYP51 Inhibition Assay for Effective Compound Triaging in Drug Discovery Programmes for Chagas Disease. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0004014.	1.3	43
17	Lead Optimization of a Pyrazole Sulfonamide Series of <i>Trypanosoma brucei</i> N-Myristoyltransferase Inhibitors: Identification and Evaluation of CNS Penetrant Compounds as Potential Treatments for Stage 2 Human African Trypanosomiasis. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 9855-9869.	2.9	57
18	Discovery of a Novel Class of Orally Active Trypanocidal N-Myristoyltransferase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 140-152.	2.9	102

#	ARTICLE	IF	CITATIONS
19	N-myristoyltransferase inhibitors as new leads to treat sleeping sickness. Nature, 2010, 464, 728-732.	13.7	272